Krystal Biotech, Inc. Common Stock KRYS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-06T14:52:33.398Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T14:50:49.290159556Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-06T14:52:33.296288+00:00
Krystal Biotech, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 326.97 | 44.7% | 9.3% | 280.67 | 47.4% | 8.1% |
| 25Δ | 320.38 | 41.5% | 7.3% | 284.84 | 47.5% | 7.1% |
| 30Δ | 316.80 | 42.0% | 6.5% | 289.00 | 47.6% | 6.1% |
| 35Δ | 313.40 | 42.8% | 5.8% | 292.77 | 47.4% | 5.3% |
| 40Δ | 310.00 | 43.6% | 5.0% | 296.42 | 47.0% | 4.6% |
| 45Δ | 306.70 | 44.1% | 4.5% | 300.06 | 46.6% | 3.9% |
| 50Δ | 303.39 | 44.6% | 3.9% | 303.50 | 46.2% | 3.3% |
| 55Δ | 300.09 | 45.0% | 3.3% | 306.93 | 45.8% | 2.8% |
| 60Δ | 296.51 | 45.6% | 2.9% | 310.39 | 45.4% | 2.3% |
| 65Δ | 292.93 | 46.2% | 2.4% | 314.04 | 44.9% | 1.9% |
| 70Δ | 289.17 | 46.9% | 2.0% | 317.69 | 44.4% | 1.5% |
| 75Δ | 284.68 | 47.8% | 1.6% | 321.68 | 43.9% | 1.1% |
| 80Δ | 280.19 | 48.7% | 1.3% | 326.26 | 43.5% | 0.8% |
20Δ
- Pseudo strike
- 326.97
- IV
- 44.7%
- B/E move
- 9.3%
- Pseudo strike
- 280.67
- IV
- 47.4%
- B/E move
- 8.1%
25Δ
- Pseudo strike
- 320.38
- IV
- 41.5%
- B/E move
- 7.3%
- Pseudo strike
- 284.84
- IV
- 47.5%
- B/E move
- 7.1%
30Δ
- Pseudo strike
- 316.80
- IV
- 42.0%
- B/E move
- 6.5%
- Pseudo strike
- 289.00
- IV
- 47.6%
- B/E move
- 6.1%
35Δ
- Pseudo strike
- 313.40
- IV
- 42.8%
- B/E move
- 5.8%
- Pseudo strike
- 292.77
- IV
- 47.4%
- B/E move
- 5.3%
40Δ
- Pseudo strike
- 310.00
- IV
- 43.6%
- B/E move
- 5.0%
- Pseudo strike
- 296.42
- IV
- 47.0%
- B/E move
- 4.6%
45Δ
- Pseudo strike
- 306.70
- IV
- 44.1%
- B/E move
- 4.5%
- Pseudo strike
- 300.06
- IV
- 46.6%
- B/E move
- 3.9%
50Δ
- Pseudo strike
- 303.39
- IV
- 44.6%
- B/E move
- 3.9%
- Pseudo strike
- 303.50
- IV
- 46.2%
- B/E move
- 3.3%
55Δ
- Pseudo strike
- 300.09
- IV
- 45.0%
- B/E move
- 3.3%
- Pseudo strike
- 306.93
- IV
- 45.8%
- B/E move
- 2.8%
60Δ
- Pseudo strike
- 296.51
- IV
- 45.6%
- B/E move
- 2.9%
- Pseudo strike
- 310.39
- IV
- 45.4%
- B/E move
- 2.3%
65Δ
- Pseudo strike
- 292.93
- IV
- 46.2%
- B/E move
- 2.4%
- Pseudo strike
- 314.04
- IV
- 44.9%
- B/E move
- 1.9%
70Δ
- Pseudo strike
- 289.17
- IV
- 46.9%
- B/E move
- 2.0%
- Pseudo strike
- 317.69
- IV
- 44.4%
- B/E move
- 1.5%
75Δ
- Pseudo strike
- 284.68
- IV
- 47.8%
- B/E move
- 1.6%
- Pseudo strike
- 321.68
- IV
- 43.9%
- B/E move
- 1.1%
80Δ
- Pseudo strike
- 280.19
- IV
- 48.7%
- B/E move
- 1.3%
- Pseudo strike
- 326.26
- IV
- 43.5%
- B/E move
- 0.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 47.14% | |
| 47.19% | |
| 47.47% | |
| 48.25% | |
| 48.33% | |
| 49.03% | |
| 48.83% | |
| 49.17% | |
| 49.15% | |
| 50.09% |
Biotechnology
KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego,…
More →KYMR
Description unavailable
More →KYTX
Description unavailable
More →KZIA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
More →LBRX
Description unavailable
More →LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the…
More →